These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31325529)

  • 41. NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.
    Marampon F; Codenotti S; Megiorni F; Del Fattore A; Camero S; Gravina GL; Festuccia C; Musio D; De Felice F; Nardone V; Santoro AN; Dominici C; Fanzani A; Pirtoli L; Fioravanti A; Tombolini V; Cheleschi S; Tini P
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):881-893. PubMed ID: 30701326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization.
    Petragnano F; Pietrantoni I; Camero S; Codenotti S; Milazzo L; Vulcano F; Macioce G; Giordani I; Tini P; Cheleschi S; Gravina GL; Festuccia C; Rossetti A; Delle Monache S; Ordinelli A; Ciccarelli C; Mauro A; Barbara B; Antinozzi C; Schiavetti A; Maggio R; Di Luigi L; Polimeni A; Marchese C; Tombolini V; Fanzani A; Bernabò N; Megiorni F; Marampon F
    J Biomed Sci; 2020 Aug; 27(1):90. PubMed ID: 32854690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
    Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
    Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
    Qian X; Ara G; Mills E; LaRochelle WJ; Lichenstein HS; Jeffers M
    Int J Cancer; 2008 Mar; 122(6):1400-10. PubMed ID: 18027850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
    Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
    J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
    Kutko MC; Glick RD; Butler LM; Coffey DC; Rifkind RA; Marks PA; Richon VM; LaQuaglia MP
    Clin Cancer Res; 2003 Nov; 9(15):5749-55. PubMed ID: 14654560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective Targeting of Myoblast Fusogenic Signaling and Differentiation-Arrest Antagonizes Rhabdomyosarcoma Cells.
    Granados VA; Avirneni-Vadlamudi U; Dalal P; Scarborough SR; Galindo KA; Mahajan P; Galindo RL
    Cancer Res; 2019 Sep; 79(18):4585-4591. PubMed ID: 31331911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.
    Shen J; Hong Y; Zhao Q; Zhang JL
    Tumour Biol; 2016 Jan; 37(1):1025-33. PubMed ID: 26269112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report.
    Kusaczuk M; Krętowski R; Stypułkowska A; Cechowska-Pasko M
    Invest New Drugs; 2016 Oct; 34(5):552-64. PubMed ID: 27468826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
    Ong PS; Wang L; Chia DM; Seah JY; Kong LR; Thuya WL; Chinnathambi A; Lau JY; Wong AL; Yong WP; Yang D; Ho PC; Sethi G; Goh BC
    Cancer Lett; 2016 Oct; 381(1):49-57. PubMed ID: 27461583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma.
    Phelps MP; Bailey JN; Vleeshouwer-Neumann T; Chen EY
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15090-15095. PubMed ID: 27956629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
    Kim MJ; Lee JS; Park SE; Yi HJ; Jeong IG; Kang JS; Yun J; Lee JY; Ro S; Lee JS; Choi EK; Hwang JJ; Kim CS
    J Urol; 2015 May; 193(5):1660-8. PubMed ID: 25433307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reactive Oxygen Species (ROS)-Inducing Triterpenoid Inhibits Rhabdomyosarcoma Cell and Tumor Growth through Targeting Sp Transcription Factors.
    Kasiappan R; Jutooru I; Mohankumar K; Karki K; Lacey A; Safe S
    Mol Cancer Res; 2019 Mar; 17(3):794-805. PubMed ID: 30610105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
    Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
    Hamam HJ; Palaniyar N
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
    Chen YJ; Wang WH; Wu WY; Hsu CC; Wei LR; Wang SF; Hsu YW; Liaw CC; Tsai WC
    PLoS One; 2017; 12(8):e0183368. PubMed ID: 28829799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA.
    Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y
    Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.